This FAQ discusses the PROTECT series of FDA clinical studies, which includes PROTECT I, the PROTECT II RCT and PROTECT III, is the largest-ever study of hemodynamically supported high-risk PCI patients.
Mitul Patel, M.D., Alexander Truesdell, M.D. and Katherine Kunkel, M.D., discuss the implications of the DanGer Shock RCT for community and academic centers.
Jena Billig discusses heparin-free purge solution and the features of the second-generation Impella 5.5® with SmartAssist® in this critical care transport webinar.
The significance of the DanGer Shock trial lies in its milestone findings for cardiology, potentially reshaping patient care by establishing routine Impella use as a life-saving intervention for STEMI patients with shock.
This overview article provides a framework for this series of articles. It addresses European recommendations and best practices for patient management and mechanical circulatory support (MCS) during high risk intervention, highlighting the following topics...
NPS-1674
This information is intended for use by customers, patients, and healthcare professionals in [region] only. We recognize that the Internet is a global communications medium; however, laws, regulatory requirements, and product information for medical products can vary from country to country. The product information included here may not be appropriate for use outside [region], and the information from other sites you visit may not be appropriate for use in [region].
The Protected PCI community
is now on HeartRecovery.com
Providing education and training to help health care professionals
recover hearts, oxygenate the body and save lives.
